Advertisement

Topics

Latest "Achillion Reports Preliminary Proof Concept With 4471 Treatment" News Stories - Page: 20

23:47 EDT 20th March 2019 | BioPortfolio

Here are the most relevant search results for "Achillion Reports Preliminary Proof Concept With 4471 Treatment" found in our extensive news archives from over 250 global news sources.

More Information about Achillion Reports Preliminary Proof Concept With 4471 Treatment on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Achillion Reports Preliminary Proof Concept With 4471 Treatment for you to read. Along with our medical data and news we also list Achillion Reports Preliminary Proof Concept With 4471 Treatment Clinical Trials, which are updated daily. BioPortfolio also has a large database of Achillion Reports Preliminary Proof Concept With 4471 Treatment Companies for you to search.

Showing "Achillion Reports Preliminary Proof Concept With 4471 Treatment" News Articles 476–500 of 22,000+

Friday 15th March 2019

Roche scores two EU approvals in haemophilia and rare autoimmune disease

The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab). The approval comes as the EC approved Roche's MabThera (rituximab) for the rare autoimmune disease pemphigus vulgaris (PV) marking the first major advancement in treatment fo the disease in more than 60 years. Hemlibra, a bispecific antibody targeting factor IXa- and factor X was approved as a treatme...


MSD's Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer

MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with metastatic squamous non-small cell lung cancer (NSCLC) when used in combination with carboplatin and either paclitaxel or nab-paclitaxel, it has emerged. Phase 3 data submitted in support of the application illustrated that the combo “signific...

- 23andMe to offer genetic reports on #diabetes - Dutch pharmacists dodge #Novartis #cancer drug market exclusivity - New class of drugs offer alternative to #statins - Sandoz #CEO Richard Francis to step down http://bit.ly/2O6DJ2e  #pharmapic.twitter.

- 23andMe to offer genetic reports on #diabetes - Dutch pharmacists dodge #Novartis #cancer drug market exclusivity - New class of drugs offer alternative to #statins - Sandoz #CEO Richard Francis to step down http://bit.ly/2O


Earpods for Cell Phones — Are There Health Risks?

A recent flurry of media reports have suggested that there may be health risks with using wireless ear pods with cell phones, but is there cause to worry? Medscape Medical News

UK’s NICE recommends pertuzumab with biosimilar trastuzumab

The UK’s National Institute for Health and Care Excellence (NICE) has recommended originator pertuzumab with intravenous biosimilar trastuzumab and chemotherapy for the treatment of breast cancer.

Achilles On Getting ‘New Wave’ Immunotherapy From Concept To Clinic In Three Years

Clonal neoantigen immunotherapy developer Achilles Therapeutics tells the Pink Sheet how the regulatory landscape for advance...

SCYNEXIS says Phase 3 program underway for treatment of acute yeast infection

The biotech expects top-line data on the use of oral ibrexafungerp for acute vulvovaginal candidiasis (VVC) in the first half of 2020

Expanded indication for hemophilia A therapy approved by EC

Roche Holding and Chugai Pharma UK announced that Hemlibra, or emicizumab, a treatment to prevent bleeding episodes in patien -More- 

Slit Lamp Microscope Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Slit Lamp Microscope report provides an independent information about the Slit Lamp Microscope industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development...

New Project to Improve Diagnosis and Treatment of Ovarian Cancer

This project will involve collaboration with 5 key industrial partners - Porvair Sciences, Bruker UK, GE Healthcare UK, Axis Bio and GlaxoSmithKline (GSK).  A new Antibody Drug Conjugates company will join the project in its second year. Antibody Drug Conjugates (ADC’s) are a powerful new class of therapeutics in medical oncology, where antibodies that target specific cancers are coupl...

Burden of Autism in Teens Weighs Heaviest on Minorities, Poor

FRIDAY, March 15, 2019 -- Autism exacts a heavy toll on the families of teens who struggle with the disorder, but the fight to get treatment and services is even harder among minorities who live in poverty, new research suggests. "We must understand...

Infertility Therapy Leads to Increased Risk of Severe Maternal Morbidity

Women undergoing infertility treatment, particularly in vitro fertilization, are at higher risk of severe maternal morbidity, but the overall risk remains low.

Arcadia Biosciences Receives FDA Approval for SONOVA® GLA Safflower Oil in Cat Food

-- SONOVA GLA offers cat food manufacturers a sustainable, plant-based source of essential omega-6 fatty acid -- Expanding on the United States Food And Drug Administration’s (FDA) 2017 approval of gamma linolenic acid (GLA) safflower oil as both safe and nutritious for use in canine diets, Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural fo...

Acute Treatment of Pediatric Migraine

Migraines occur in young children, but may be challenging to diagnose. Migraines can have a great impact on pediatric patients’ quality of life with school absence and limitations on extracurricular activities. Treatment of pediatric migraines or possible migraines is difficult secondary to the lack of evidence for effective therapies in pediatric patients. Treatment includes traditional the...

Metrohm offers standardized methods to measure critical parameters for wastewater analysis in treatment plants

Operators of wastewater treatment plants depend on reliable methods to monitor plant performance.

Nicox signs agreement for ZERVIATE in China for up to €17 million in milestone payments plus royalties

Press Release Nicox signs agreement for ZERVIATETM in China for up to €17 million in milestone payments plus royalties ................................................March 15, 2019- release at 7:30 am CETSophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, and Ocumension Therapeutics today announced they have entered ...

European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease

F. Hoffmann-La Roche Ltd / European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), an...

Truck NVH Material Global Market Research and Forecast, 20152025 [Report Updated: 01011970] Prices from USD $2200

SummaryThe Truck NVH Material report provides an independent information about the Truck NVH Material industry supported by extensive research on factors such as industry segmentssize trends, inhibitors, dynamics, drivers, opportunities challenges, environment policy, cost overview, porter's five force analysis, and key companies profiles including business overview and recent development.The...

EC Approves Roche's MabThera For Rare Autoimmune Disease

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) said that the European Commission has approved MabThera or rituximab for the treatment of adults with moderate to severe pemphigus vulgaris or PV, a r...

Amsterdam University Medical Center to Be First Dutch Hospital to Adopt Real-Time MRI-Guided Cardiac Ablations

Imricor signs first commercial contract in the Netherlands for the Advantage-MR system. Imricor announced today that it signed its first commercialization contract in the Netherlands with the Amsterdam University Medical Center, location VUmc, for the Advantage-MR™ EP Recorder/Stimulator System. With this agreement, Amsterdam UMC will become the firs...

Oral complications are rare after osteoporosis treatment denosumab highlights research

The risk of osteonecrosis of the jaw is low compared to the fracture prevention benefits of antiresorptive therapy denosumab in older women with osteoporosis, according to findings reported in The Journal of Clinical Endocrinology and Metabolism. Researchers analysed data from a seven-year study of denosumab that involved 3,591 postmenopausal women aged 60 to 90 years […] The post Oral compl...

CSE Cannabis New Listing: Orchid Ventures Inc. (CSE: ORCD)

March 15, 2019 (Investorideas.com Newswire) TheCSE.com reports The common shares of Orchid Ventures Inc., have been approved for listing on the CSE.

European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease

Roche today announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by progressive painful blistering of the skin and/or mucous membranes.

Halo Labs Announces Repricing of Convertible Debenture Units and An Increase in The Expected Size of The Offering

Halo Labs Inc. ("Halo" or the "Company") (NEO: HALO, OTC: AGEEF, Germany: A9KN) announces that it has agreed to amend the terms of its previously announced "best efforts" offering (the "Offering") of convertible debenture units (the "Convertible Debenture Units") to lower the conversion price at which the converti...

ATOS Skyrockets, BPMX Gets "Going Concern" Warning, Respite For KPTI

Today's Daily Dose brings you news about the positive progress of Atossa Genetics' Oral Endoxifen as a post-mastectomy treatment for breast cancer; BioLife Solutions' stellar fourth-quarter financial results; BioPharmX Corp's anticipated milestones in 2019; revised FDA decision date of Karyopharm's Selinexor; and clinical trial catalysts of SCYNEXIS.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks